The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels
1 other identifier
interventional
60
0 countries
N/A
Brief Summary
To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Aug 2013
Shorter than P25 for phase_4
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2013
CompletedFirst Submitted
Initial submission to the registry
August 19, 2013
CompletedFirst Posted
Study publicly available on registry
August 21, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedAugust 21, 2013
August 1, 2013
Same day
August 19, 2013
August 19, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
the serum level of VEGF,MMP-9 and EPC
0-7days
Secondary Outcomes (1)
National Institute of Health of stroke scale
0-7days
Study Arms (3)
Erigeron Injection
EXPERIMENTALErigeron Injection, 30ml,qd,i.v., for 7 days
placebo
PLACEBO COMPARATORnormal saline, 500ml,i.v.,qd, for 7 days
health volunteers
NO INTERVENTIONhealth volunteers, no drug to be given.
Interventions
normal saline, 500ml,i.v.,qd, for 7 days
Eligibility Criteria
You may qualify if:
- patients aged no younger than 18yrs
- attack within 72 hours
- NIHSS score in the 2-25 points
- Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae
- Signed the informed consents
You may not qualify if:
- patients aged younger than 18yrs
- Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation
- Patients with severe cognitive impairment
- Refused to cooperate or been unable to cooperation for neurological disorders
- Cerebral hemorrhage or hemorrhagic cerebral infarction
- Unstable vital signs dued to massive cerebral infarction
- Patients with serious heart, liver and renal insufficiency
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jianwen m Guo, doctor
Guangdong Province Hospital of Tradtional Chinese Medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2013
First Posted
August 21, 2013
Study Start
August 1, 2013
Primary Completion
August 1, 2013
Study Completion
March 1, 2014
Last Updated
August 21, 2013
Record last verified: 2013-08